Engineered Commensals Modulate Gut-Liver-Brain Axis in Hepatic Encephalopathy
Recent research published in Cell highlights a significant advancement in treating hepatic encephalopathy through the use of engineered commensal bacteria. Scientists developed specific strains of Lactobacillus plantarum designed to metabolize ammonia and reshape amino acid balance within the body. In experiments conducted on two distinct mouse models, the treatment demonstrated remarkable efficacy by significantly lowering ammonia levels in both the blood and the brain. Furthermore, the intervention led to noticeable improvements in anxiety-like behaviors associated with the condition. A key finding of the study is that this therapeutic approach preserves gut microbiota diversity, addressing a common concern with traditional antibiotic treatments. Importantly, the engineered bacterial strains are naturally cleared from the system once dosing stops, suggesting a favorable safety profile for potential clinical applications. This study underscores the potential of synthetic biology and microbiome engineering in modulating the complex gut-liver-brain axis, offering a novel therapeutic avenue for metabolic disorders affecting neurological health.
Wire timeline
Engineered Commensals Modulate Gut-Liver-Brain Axis in Hepatic Encephalopathy
Recent research published in Cell highlights a significant advancement in treating hepatic encephalopathy through the use of engineered commensal bacteria. Scientists developed specific strains of Lactobacillus plantarum designed to metabolize ammonia and reshape amino acid balance within the body. In experiments conducted on two distinct mouse models, the treatment demonstrated remarkable efficacy by significantly lowering ammonia levels in both the blood and the brain. Furthermore, the intervention led to noticeable improvements in anxiety-like behaviors associated with the condition. A key finding of the study is that this therapeutic approach preserves gut microbiota diversity, addressing a common concern with traditional antibiotic treatments. Importantly, the engineered bacterial strains are naturally cleared from the system once dosing stops, suggesting a favorable safety profile for potential clinical applications. This study underscores the potential of synthetic biology and microbiome engineering in modulating the complex gut-liver-brain axis, offering a novel therapeutic avenue for metabolic disorders affecting neurological health.
Cell